- Home
- REBN vs CLRB Comparison
REBN vs CLRB Comparison
Compare REBN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- CLRB
- Stock Information
- Founded
- REBN 2015
- CLRB 2002
- Country
- REBN United States
- CLRB United States
- Employees
- REBN N/A
- CLRB N/A
- Industry
- REBN Restaurants
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- CLRB Health Care
- Exchange
- REBN Nasdaq
- CLRB Nasdaq
- Market Cap
- REBN 15.3M
- CLRB 14.2M
- IPO Year
- REBN 2022
- CLRB N/A
- Fundamental
- Price
- REBN $2.45
- CLRB $4.98
- Analyst Decision
- REBN
- CLRB Hold
- Analyst Count
- REBN 0
- CLRB 2
- Target Price
- REBN N/A
- CLRB N/A
- AVG Volume (30 Days)
- REBN 93.6K
- CLRB 154.8K
- Earning Date
- REBN 08-14-2025
- CLRB 08-14-2025
- Dividend Yield
- REBN N/A
- CLRB N/A
- EPS Growth
- REBN N/A
- CLRB N/A
- EPS
- REBN N/A
- CLRB N/A
- Revenue
- REBN $6,565,623.00
- CLRB N/A
- Revenue This Year
- REBN $335.98
- CLRB N/A
- Revenue Next Year
- REBN N/A
- CLRB N/A
- P/E Ratio
- REBN N/A
- CLRB N/A
- Revenue Growth
- REBN 14.03
- CLRB N/A
- 52 Week Low
- REBN $1.03
- CLRB $4.11
- 52 Week High
- REBN $8.30
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- REBN 34.79
- CLRB 51.74
- Support Level
- REBN $2.91
- CLRB $4.43
- Resistance Level
- REBN $3.24
- CLRB $5.08
- Average True Range (ATR)
- REBN 0.19
- CLRB 0.40
- MACD
- REBN -0.06
- CLRB 0.10
- Stochastic Oscillator
- REBN 10.91
- CLRB 73.11
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.